The Medicines Co (MDCO)

38.15
0.68 1.80
NASDAQ : Health Care
Prev Close 38.83
Open 38.80
Day Low/High 37.93 / 39.37
52 Wk Low/High 27.50 / 43.79
Volume 1.25M
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 72.17M
Market Cap 2.71B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Medicines Company Reports First-Quarter 2017 Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017.

The Medicines Company And Alnylam Pharmaceuticals Announce Agreement With FDA On Phase III Clinical Program For Inclisiran

The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc.

The Medicines Company To Present Data At ECCMID 2017 On Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam

The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the 27 th Annual European...

The Medicines Company To Announce First-Quarter 2017 Financial Results On April 26, 2017

The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, April 26, 2017, at 8:30 a.

The Medicines Company Appoints Paris Panayiotopoulos To Its Board Of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Paris Panayiotopoulos to its Board of Directors.

The Medicines Company To Present At Needham Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 8:00 a.

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

Here's how to trade six of the most active names on the market this past week.

The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion Therapeutics, Medicines Co. and Amgen were among the biotech stock movers Friday morning.

The Medicines Company To Webcast Presentation Of ORION-1 Phase II Study Of Inclisiran At ACC.17

The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneously with the presentation, the detailed results from its ORION-1 Phase II study of inclisiran, the Company's...

The Medicines Company To Host Conference Call And Webcast At Upcoming American College Of Cardiology's 66th Annual Scientific Sessions

The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.

The Medicines Company Reports Fourth-Quarter And Full-Year 2016 Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its financial results for the fourth-quarter and full-year ended December 31, 2016.

The Medicines Company To Announce Fourth-Quarter And Full-Year 2016 Financial Results On February 28, 2017

The Medicines Company (NASDAQ:MDCO) will host a conference call on Tuesday, February 28, 2017, at 8:30 a.

Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.

Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.

Ardelyx, Acorda Therapeutics and Medicines Co. were among the premarket biotech movers on Wednesday.

Insiders Seeing Green With MDCO At New 52-Week High

In trading on Friday, shares of Medicines Co touched a new 52-week high of $45.31/share. That's a 64.76% rise, or $17.81 per share from the 52-week low of $27.50 set back on 02/11/2016.

Premarket Biotech Movers: Portola, Esperion, Medicines

Premarket Biotech Movers: Portola, Esperion, Medicines

Portola Pharmaceuticals, Esperion Therapeutics and Medicines were among the biotech stock movers in premarket trading on Friday.

The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session

The Medicines Company To Present Results From ORION-1 Phase 2 Study Of Inclisiran At The American College Of Cardiology's 66th Annual Scientific Session

The Medicines Company (Nasdaq: MDCO) today announced that full safety and efficacy data from the ORION-1 Phase 2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the...

The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)

The Medicines Company Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (formerly, PCSK9si)

The Medicines Company (Nasdaq:MDCO) today announced positive top-line results from the interim analysis with Day 180 follow-up for all 501 patients enrolled in the ongoing ORION-1 Phase 2 study of inclisiran, its...

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

The Medicines Company To Present At J. P. Morgan Healthcare Conference

The Medicines Company To Present At J. P. Morgan Healthcare Conference

The Medicines Company (Nasdaq: MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Medtronic and Medicines -- have been scooping up shares of their own stock lately.

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc.

Http://www.themedicinescompany.com/

Http://www.themedicinescompany.com/

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Tuesday, November 15, 2016, at 3:00 p.

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company (NASDAQ:MDCO) announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its financial results for the third quarter ended September 30, 2016.

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class...